JP2018042573A5 - - Google Patents

Download PDF

Info

Publication number
JP2018042573A5
JP2018042573A5 JP2017247587A JP2017247587A JP2018042573A5 JP 2018042573 A5 JP2018042573 A5 JP 2018042573A5 JP 2017247587 A JP2017247587 A JP 2017247587A JP 2017247587 A JP2017247587 A JP 2017247587A JP 2018042573 A5 JP2018042573 A5 JP 2018042573A5
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding fragment
cancer
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017247587A
Other languages
English (en)
Japanese (ja)
Other versions
JP6480558B2 (ja
JP2018042573A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018042573A publication Critical patent/JP2018042573A/ja
Publication of JP2018042573A5 publication Critical patent/JP2018042573A5/ja
Application granted granted Critical
Publication of JP6480558B2 publication Critical patent/JP6480558B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017247587A 2012-08-31 2017-12-25 葉酸受容体１の検出のための診断分析およびキット Active JP6480558B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261695791P 2012-08-31 2012-08-31
US61/695,791 2012-08-31
US201361756254P 2013-01-24 2013-01-24
US61/756,254 2013-01-24

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015530124A Division JP6293147B2 (ja) 2012-08-31 2013-08-30 葉酸受容体１の検出のための診断分析およびキット

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018052302A Division JP2018088942A (ja) 2012-08-31 2018-03-20 葉酸受容体１の検出のための診断分析およびキット

Publications (3)

Publication Number Publication Date
JP2018042573A JP2018042573A (ja) 2018-03-22
JP2018042573A5 true JP2018042573A5 (OSRAM) 2018-05-10
JP6480558B2 JP6480558B2 (ja) 2019-03-13

Family

ID=50184673

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2015530124A Active JP6293147B2 (ja) 2012-08-31 2013-08-30 葉酸受容体１の検出のための診断分析およびキット
JP2017247587A Active JP6480558B2 (ja) 2012-08-31 2017-12-25 葉酸受容体１の検出のための診断分析およびキット
JP2018052302A Withdrawn JP2018088942A (ja) 2012-08-31 2018-03-20 葉酸受容体１の検出のための診断分析およびキット
JP2019203933A Pending JP2020018325A (ja) 2012-08-31 2019-11-11 葉酸受容体１の検出のための診断分析およびキット
JP2021200640A Active JP7289346B2 (ja) 2012-08-31 2021-12-10 葉酸受容体１の検出のための診断分析およびキット
JP2023088416A Pending JP2023111942A (ja) 2012-08-31 2023-05-30 葉酸受容体１の検出のための診断分析およびキット

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015530124A Active JP6293147B2 (ja) 2012-08-31 2013-08-30 葉酸受容体１の検出のための診断分析およびキット

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018052302A Withdrawn JP2018088942A (ja) 2012-08-31 2018-03-20 葉酸受容体１の検出のための診断分析およびキット
JP2019203933A Pending JP2020018325A (ja) 2012-08-31 2019-11-11 葉酸受容体１の検出のための診断分析およびキット
JP2021200640A Active JP7289346B2 (ja) 2012-08-31 2021-12-10 葉酸受容体１の検出のための診断分析およびキット
JP2023088416A Pending JP2023111942A (ja) 2012-08-31 2023-05-30 葉酸受容体１の検出のための診断分析およびキット

Country Status (27)

Country Link
US (6) US9200073B2 (OSRAM)
EP (2) EP2890717B1 (OSRAM)
JP (6) JP6293147B2 (OSRAM)
KR (4) KR20240005129A (OSRAM)
CN (2) CN104755498B (OSRAM)
AU (4) AU2013308497B2 (OSRAM)
BR (1) BR112015004229B1 (OSRAM)
CA (2) CA2883222C (OSRAM)
CY (1) CY1122907T1 (OSRAM)
DK (1) DK2890717T3 (OSRAM)
ES (1) ES2788151T3 (OSRAM)
HR (1) HRP20200482T1 (OSRAM)
HU (1) HUE049693T2 (OSRAM)
IL (4) IL299620A (OSRAM)
LT (1) LT2890717T (OSRAM)
ME (1) ME03799B (OSRAM)
MX (2) MX378788B (OSRAM)
NZ (2) NZ630433A (OSRAM)
PL (1) PL2890717T3 (OSRAM)
PT (1) PT2890717T (OSRAM)
RS (1) RS60217B1 (OSRAM)
RU (1) RU2668824C2 (OSRAM)
SG (2) SG11201500938XA (OSRAM)
SI (1) SI2890717T1 (OSRAM)
SM (1) SMT202000158T1 (OSRAM)
WO (1) WO2014036495A2 (OSRAM)
ZA (1) ZA201707245B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230044026A (ko) 2010-02-24 2023-03-31 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
UA125636C2 (uk) * 2011-04-01 2022-05-11 Іммуноджен, Інк. Способи ідентифікації раку, який може реагувати на анти-folr1 антитіло або анти-folr1 імунокон'югат
JP6293147B2 (ja) 2012-08-31 2018-03-14 イミュノジェン， インコーポレイテッド 葉酸受容体１の検出のための診断分析およびキット
WO2014205342A2 (en) * 2013-06-20 2014-12-24 Morphotek, Inc. Methods for treatment of ovarian cancer
LT3038650T (lt) 2013-08-30 2021-09-10 Immunogen, Inc. Antikūnai ir foliatų receptoriaus 1 nustatymo testai
WO2015054400A2 (en) * 2013-10-08 2015-04-16 Immunogen, Inc. Anti-folr1 immunoconjugate dosing regimens
US20150297744A1 (en) * 2014-03-28 2015-10-22 Immunogen, Inc. Anti-FOLR1 Immunoconjugate Dosing Regimens
JPWO2015186823A1 (ja) * 2014-06-06 2017-04-20 協和発酵キリン株式会社 Ｆｏｌｒ１標的薬および葉酸代謝拮抗剤によるがん患者のための治療方法並びに医薬
SG11201702976TA (en) * 2014-11-20 2017-05-30 Hoffmann La Roche T cell activating bispecific antigen binding molecules agiant folr1 and cd3
EP3349796A4 (en) 2015-09-17 2019-05-29 ImmunoGen, Inc. THERAPEUTIC COMBINATIONS WITH ANTI-FOLR1 IMMUNOCONJUGATES
CN105548059B (zh) * 2016-01-29 2018-08-24 福建医科大学 叶酸-牛血清白蛋白-铂铋纳米复合材料
US10940112B2 (en) 2016-05-04 2021-03-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
JP7072571B2 (ja) * 2016-11-23 2022-05-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗葉酸受容体アルファ抗体およびその使用
CN108982430B (zh) * 2017-05-31 2020-09-29 北京大学 标记细菌菌群样品的试剂盒、方法及应用
IL272840B2 (en) * 2017-09-05 2025-01-01 Immunogen Inc Methods for detecting folate receptor 1 in a patient sample
KR102808710B1 (ko) * 2018-03-13 2025-05-15 페인스 테라퓨틱스 인코포레이티드 항-폴레이트 수용체 1 항체 및 이의 용도
EP3953392A1 (en) * 2019-04-12 2022-02-16 Phanes Therapeutics, Inc. Humanized anti-folate receptor 1 chimeric antigen receptors and uses thereof
TWI872065B (zh) 2019-04-29 2025-02-11 美商免疫遺傳股份有限公司 雙互補位ＦＲ－α抗體及免疫結合物
CN112794911B (zh) * 2021-04-14 2021-08-03 上海偌妥生物科技有限公司 人源化抗叶酸受体1抗体及其应用
JP2024522544A (ja) * 2021-06-04 2024-06-21 イミュノジェン， インコーポレイテッド 可溶性ＦＲ－α患者におけるがんの治療
CN114163520B (zh) * 2021-11-23 2024-01-30 南京京达生物技术有限公司 一种血源性人IgM抗体纯化介质制备方法
JP2024547111A (ja) 2021-12-24 2024-12-26 バイオ－テラ ソリュ－ションズ，エルティーディー． 抗ＦＲα抗体及びその抗体薬物コンジュゲート並びに使用
CN119019546B (zh) * 2022-07-05 2025-09-05 东莞市朋志生物科技有限公司 抗乙型流感病毒抗体、检测乙型流感病毒的试剂和试剂盒
WO2025094146A1 (en) 2023-11-02 2025-05-08 Immunogen Switzerland Gmbh Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates
CN117700557B (zh) * 2024-02-05 2024-04-30 卡秋(江苏)生物科技有限公司 一种特异性结合叶酸受体α的抗体或抗原结合片段
CN117700556B (zh) * 2024-02-05 2024-04-12 苏州百道医疗科技有限公司 一种抗FRα小鼠单克隆抗体及其应用

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3645090A (en) 1969-06-19 1972-02-29 Citizen Watch Co Ltd Day-date quick-adjuster for calender timepiece
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU4434585A (en) 1985-03-30 1986-10-23 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5763192A (en) 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8826530D0 (en) 1988-11-12 1988-12-14 Ped Capacitors Ltd Electrical capacitors
US20030229208A1 (en) 1988-12-28 2003-12-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
EP0478627A4 (en) 1989-05-16 1992-08-19 William D. Huse Co-expression of heteromeric receptors
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
DE69130647T2 (de) 1990-08-24 1999-05-06 Ixsys, Inc., San Diego, Calif. Verfahren zur herstellung von oligonukleotiden mit regellosen codonen
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
AU9166691A (en) 1990-12-20 1992-07-22 Ixsys, Inc. Optimization of binding proteins
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
ATE249840T1 (de) 1991-12-13 2003-10-15 Xoma Corp Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US20030148406A1 (en) 1992-03-17 2003-08-07 David John King Multivalent antigen-binding proteins
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU6132994A (en) 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US6706484B1 (en) 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
US6331431B1 (en) 1995-11-28 2001-12-18 Ixsys, Inc. Vacuum device and method for isolating periplasmic fraction from cells
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6596850B1 (en) 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
WO1999006834A2 (en) 1997-08-04 1999-02-11 Ixsys, Incorporated Methods for identifying ligand specific binding molecules
EP1150688A4 (en) 1998-10-19 2004-06-16 Yeda Res & Dev TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS BY NEGATIVE REGULATION OF THE AUTO-IMMUNE RESPONSE TO AUTOANTIGENS
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
ES2353268T3 (es) 1999-07-02 2011-02-28 Morphosys Ag Generacion de elementos de union especifica que se unen a (poli)peptidos codificados por fragmentos de adn genomico o est.
IT1307309B1 (it) 1999-12-30 2001-10-30 Enea Ente Nuove Tec Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono.
EA005823B1 (ru) 2000-03-31 2005-06-30 Пердью Рисерч Фаундейшн Способ лечения с использованием конъюгатов лиганд-иммуноген
DE10037759A1 (de) 2000-08-03 2002-07-04 Gruenenthal Gmbh Screeningverfahren
EP1998266A3 (en) 2001-02-19 2009-02-11 Merck Patent GmbH Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
AU2002258518A1 (en) 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
CN1635910A (zh) 2001-05-02 2005-07-06 普渡研究基金会 巨噬细胞介导的疾病的治疗和诊断
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
WO2003074704A1 (fr) 2002-03-01 2003-09-12 Japan Envirochemicals, Ltd. Proteines capables de se lier aux hormones sexuelles feminines et procede de preparation
EP1497333A2 (en) 2002-04-22 2005-01-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Antibodies, recombinant antibodies, recombinant antibody fragments and fusions mediated plant disease resistance against fungi
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
HUE026914T2 (en) 2002-11-07 2016-08-29 Immunogen Inc Anti-CD33 antibodies and a method of treating acute myeloid leukemia
WO2004043989A2 (en) 2002-11-07 2004-05-27 Medarex, Inc. Human monoclonal antibodies to heparanase
EP1481993A1 (en) 2003-05-28 2004-12-01 Xerion Pharmaceuticals AG Modulation of the poliovirus receptor function
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
KR101412271B1 (ko) 2003-05-09 2014-06-25 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
CN1816356A (zh) 2003-05-14 2006-08-09 免疫原公司 药物缀合物组合物
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
ZA200510282B (en) 2003-07-02 2007-03-28 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
CA2548942C (en) 2003-12-05 2013-10-15 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Anti-sars monoclonal antibodies
AU2005214331B2 (en) 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
WO2005075514A2 (en) 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
MXPA06012162A (es) 2004-04-27 2007-03-30 Galapagos Nv Metodos, agentes y ensayos de seleccion de compuestos para inducir diferenciacion de celulas de mamifero no diferenciadas, en osteoblastos.
US20080312425A1 (en) 2004-08-30 2008-12-18 Lonza Biologics Plc. Ion Exchange Chromatography and Purification of Antibodies
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
NZ554725A (en) 2004-10-25 2009-10-30 Merck & Co Inc Anti-ADDL antibodies and uses thereof
WO2007044043A2 (en) 2004-12-21 2007-04-19 Monsanto Technology, Llc Transgenic plants with enhanced agronomic traits
MX2007008017A (es) 2004-12-31 2007-09-12 Genentech Inc Polipeptidos que se ligan a br3 y usos de los mismos.
CN101146554B (zh) 2005-01-27 2012-10-10 加州大学评议会 中和肉毒杆菌神经毒素的治疗性单克隆抗体
EP1866339B8 (en) 2005-03-25 2021-12-01 GITR, Inc. Gitr binding molecules and uses therefor
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
AU2006230219A1 (en) 2005-03-30 2006-10-05 Endocyte, Inc. Method for cancer prognosis using cellular folate vitamin receptor quantification
EP2172487A1 (en) * 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
WO2006121207A1 (en) 2005-05-12 2006-11-16 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-dsc2 antibody
US20090215165A1 (en) 2005-05-20 2009-08-27 James Rance High-level expression of recombinant antibody in a mammalian host cell
AU2006250888A1 (en) 2005-05-24 2006-11-30 Avesthagen Limited A method for the production of a monoclonal antibody to CD20 for the treatment of B-cell lymphoma
WO2007006041A2 (en) 2005-07-05 2007-01-11 Purdue Research Foundation Imaging and therapeutic method using monocytes
US7521195B1 (en) 2005-07-21 2009-04-21 Celera Corporation Lung disease targets and uses thereof
EP1937720B1 (en) 2005-08-18 2014-04-09 Ramot at Tel-Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
AU2006291990B2 (en) 2005-09-13 2012-05-31 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
US20070099251A1 (en) 2005-10-17 2007-05-03 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
PT2532681E (pt) 2005-12-20 2014-12-23 Sbi Biotech Co Ltd Anticorpos anti-ilt7
US8486412B2 (en) 2006-06-01 2013-07-16 Mayo Foundation For Medical Education And Research Immunity to folate receptors
EP3231442B1 (en) 2006-06-23 2019-12-25 ADC Therapeutics SA Polynucleotides and polypeptide sequences involved in cancer
US7910702B2 (en) 2006-07-28 2011-03-22 The Governors Of The University Of Alberta Recombinant antibodies to sclerotinia antigens
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
US20090182955A1 (en) 2006-09-08 2009-07-16 Rao Cherukuri Application configuration across client devices of a local system
EP1900752A1 (en) * 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
AU2007312367B2 (en) 2006-10-12 2012-09-06 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-EREG antibody
AU2007332473B2 (en) 2006-12-14 2012-09-27 Forerunner Pharma Research Co., Ltd. Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same
BRPI0720565A2 (pt) 2006-12-20 2013-09-17 Mmr Information Systems Inc anticorpos e mÉtodos para a sua preparaÇço e seu uso
US20080227704A1 (en) 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
EP2606911A1 (en) 2007-02-16 2013-06-26 KTB Tumorforschungsgesellschaft mbH Receptor And Antigen Targeted Prodrug
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
WO2008145136A1 (en) 2007-05-30 2008-12-04 Aarhus Universitet Stat3 inactivation by inhibition of the folate receptor pathway
CN104383553A (zh) 2007-06-25 2015-03-04 恩多塞特公司 含有亲水性间隔区接头的共轭物
CN101139613B (zh) 2007-08-01 2011-06-08 姜荣锡 抗肿瘤二元多肽及其应用与制备方法
CN103805633B (zh) 2007-12-21 2016-09-07 诺华股份有限公司 有机化合物
AU2009203464A1 (en) 2008-01-11 2009-07-16 Forerunner Pharma Research Co., Ltd. Anti-CLDN6 antibody
US8093364B2 (en) 2008-01-18 2012-01-10 Bio-Rad Laboratories, Inc. Enhanced purification of antibodies and antibody fragments by apatite chromatography
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
CA2722190A1 (en) 2008-04-21 2009-10-29 Swapsol Corp. Hydrogen sulfide conversion to hydrogen
WO2009132081A2 (en) 2008-04-24 2009-10-29 The Research Foundation Of State University Of New York Monoclonal antibody-based targeting of folate receptors
CN104524590B (zh) 2008-04-30 2019-06-21 伊缪诺金公司 交联剂和它们的用途
MX2010011808A (es) 2008-04-30 2011-03-04 Immunogen Inc Conjugados potentes y enlazadores hidrofilicos.
US8383351B2 (en) 2008-06-11 2013-02-26 Oxford Brookes University Antibody to inhibin/ activin β-B subunit
US20100069298A1 (en) * 2008-09-16 2010-03-18 Robert Penny Methods for Detecting Overexpression of SPARC and Therapeutic and Diagnostic Methods Relating to Same
CA2737496A1 (en) 2008-09-17 2010-03-25 Endocyte, Inc. Folate receptor binding conjugates of antifolates
WO2010033913A1 (en) 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
CN101440130B (zh) 2008-11-21 2011-07-27 中国人民解放军第四军医大学 一种抗人IL-13Rα2单克隆抗体的重链和轻链的可变区
CN110470835A (zh) 2009-03-24 2019-11-19 生物概念股份有限公司 细胞捕获和分析的装置和方法
WO2011010652A1 (ja) * 2009-07-23 2011-01-27 株式会社資生堂 油中水型乳化化粧料
ES2624835T3 (es) * 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
WO2011100398A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc. Cd20 antibodies and uses thereof
KR20230044026A (ko) * 2010-02-24 2023-03-31 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
KR20140032944A (ko) * 2010-10-20 2014-03-17 모르포테크, 인크. 항폴레이트 수용체 알파 항체 당형태
WO2012061759A2 (en) * 2010-11-05 2012-05-10 Morphotek Inc. Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
EP2691117A2 (en) 2011-03-29 2014-02-05 Immunogen, Inc. Process for manufacturing conjugates of improved homogeneity
SMT201900114T1 (it) 2011-03-29 2019-02-28 Immunogen Inc Preparazione di coniugati maytansinoide-anticorpo mediante un processo a fase unica
UA125636C2 (uk) 2011-04-01 2022-05-11 Іммуноджен, Інк. Способи ідентифікації раку, який може реагувати на анти-folr1 антитіло або анти-folr1 імунокон'югат
WO2012138749A1 (en) 2011-04-04 2012-10-11 Immunogen, Inc. Methods for decreasing ocular toxicity of antibody drug conjugates
CA2841725C (en) 2011-07-15 2021-03-09 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
JP6293147B2 (ja) 2012-08-31 2018-03-14 イミュノジェン， インコーポレイテッド 葉酸受容体１の検出のための診断分析およびキット
EP2930240B1 (en) 2012-12-07 2018-08-01 Kyowa Hakko Kirin Co., Ltd. Anti-folr1 antibody
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
RU2015149285A (ru) 2013-05-14 2017-06-19 Иммьюноджен Инк. Схемы дозирования иммуноконъюгата anti-folr1
LT3038650T (lt) 2013-08-30 2021-09-10 Immunogen, Inc. Antikūnai ir foliatų receptoriaus 1 nustatymo testai
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
WO2015054400A2 (en) 2013-10-08 2015-04-16 Immunogen, Inc. Anti-folr1 immunoconjugate dosing regimens
US20150297744A1 (en) 2014-03-28 2015-10-22 Immunogen, Inc. Anti-FOLR1 Immunoconjugate Dosing Regimens
EP3349796A4 (en) 2015-09-17 2019-05-29 ImmunoGen, Inc. THERAPEUTIC COMBINATIONS WITH ANTI-FOLR1 IMMUNOCONJUGATES
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Similar Documents

Publication Publication Date Title
JP2018042573A5 (OSRAM)
US11525003B2 (en) Anti-B7-H3 antibodies and diagnostic uses thereof
JP2015533788A5 (OSRAM)
AU2016333538B2 (en) GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
JP6239503B2 (ja) 新規な抗ｃｘｃｒ４抗体並びに癌の検出および診断のためのその使用
JP7022191B2 (ja) 前立腺がんの分析のための組成物及び方法
JP5941615B2 (ja) ヒトｃｘｃｌ１タンパク質の免疫学的測定方法
JP6324970B2 (ja) 抗ウロプラキンｉｉ抗体システムおよび方法
JP2017518366A5 (OSRAM)
KR102366820B1 (ko) 진단을 위한 세포 표면 전립선암 항원
JP6138780B2 (ja) 癌の検出および診断のための抗体ｉ−３８５９の使用
RU2013142334A (ru) КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ ДЛЯ ОПРЕДЕЛЕНИЯ НЕ4а
JP2011509079A5 (OSRAM)
JP2018527895A5 (OSRAM)
WO2019066617A2 (ko) 항 c-met 항체 및 이의 용도
US20190359722A1 (en) Anti-epha2 antibody and immunological detection of epha2 using same
WO2019066620A2 (ko) 항 c-met 항체 및 이의 용도
CN104830805B (zh) 抗人翻译控制肿瘤蛋白单克隆抗体杂交瘤及其单克隆抗体与应用
CN104830804B (zh) 一种翻译控制肿瘤蛋白的单克隆抗体杂交瘤及其单克隆抗体与应用
WO2023077172A2 (en) Novel anti-lilrb2 antibodies and derivative products
KR102688094B1 (ko) Cobll1 단백질 특이 항체 또는 이의 항원 결합 단편, 및 이의 용도
CN121219584A (zh) 针对nr1的自身抗体的检测
Vasconcellosa et al. Generation and characterization of new HER2 monoclonal antibodies